IL258638B2 - Antibodies with polyvalent variable segment - Google Patents

Antibodies with polyvalent variable segment

Info

Publication number
IL258638B2
IL258638B2 IL258638A IL25863818A IL258638B2 IL 258638 B2 IL258638 B2 IL 258638B2 IL 258638 A IL258638 A IL 258638A IL 25863818 A IL25863818 A IL 25863818A IL 258638 B2 IL258638 B2 IL 258638B2
Authority
IL
Israel
Prior art keywords
polypeptide
variable domains
pair
unit
variable
Prior art date
Application number
IL258638A
Other languages
English (en)
Hebrew (he)
Other versions
IL258638B (en
IL258638A (en
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of IL258638A publication Critical patent/IL258638A/en
Publication of IL258638B publication Critical patent/IL258638B/en
Publication of IL258638B2 publication Critical patent/IL258638B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL258638A 2015-10-13 2016-10-13 Antibodies with polyvalent variable segment IL258638B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies
PCT/EP2016/074642 WO2017064221A1 (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Publications (3)

Publication Number Publication Date
IL258638A IL258638A (en) 2018-06-28
IL258638B IL258638B (en) 2022-12-01
IL258638B2 true IL258638B2 (en) 2023-04-01

Family

ID=54325413

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258638A IL258638B2 (en) 2015-10-13 2016-10-13 Antibodies with polyvalent variable segment

Country Status (13)

Country Link
US (1) US11572415B2 (cg-RX-API-DMAC7.html)
EP (2) EP3156417A1 (cg-RX-API-DMAC7.html)
JP (1) JP6936497B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180057720A (cg-RX-API-DMAC7.html)
CN (1) CN108473577A (cg-RX-API-DMAC7.html)
AU (1) AU2016336866B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018007445A2 (cg-RX-API-DMAC7.html)
CA (1) CA3001765A1 (cg-RX-API-DMAC7.html)
IL (1) IL258638B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018004547A (cg-RX-API-DMAC7.html)
SG (2) SG11201803083XA (cg-RX-API-DMAC7.html)
WO (1) WO2017064221A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201802543B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6839101B2 (ja) 2015-06-15 2021-03-03 ヌマブ セラピューティクス アクチェンゲゼルシャフト ヘテロ二量体多重特異性抗体フォーマット
CN117946278A (zh) * 2017-06-25 2024-04-30 西雅图免疫公司 多特异性抗体及其制备和使用方法
WO2019175368A1 (en) 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
CN111527108A (zh) * 2018-03-27 2020-08-11 西雅图免疫公司 制导和导航控制蛋白的制造和使用方法
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
MX2020010728A (es) * 2018-04-13 2020-11-06 Affimed Gmbh Constructos de fusion de anticuerpos que se acoplan a celulas nk.
AU2019255270A1 (en) * 2018-04-17 2020-11-19 Invenra Inc. Trivalent trispecific antibody constructs
PL3843757T3 (pl) 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
EP4034245A1 (en) * 2019-09-25 2022-08-03 Universität Stuttgart Trivalent binding molecules
CN118599006A (zh) * 2019-11-06 2024-09-06 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
CA3203468A1 (en) * 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains
WO2022174813A1 (zh) * 2021-02-19 2022-08-25 信达生物制药(苏州)有限公司 抗GPRC5DxBCMAxCD3三特异性抗体及其用途
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
AU2022356387A1 (en) * 2021-09-29 2024-04-18 Modex Therapeutics, Inc. Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
US20230272069A1 (en) * 2022-02-28 2023-08-31 Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135345A1 (en) * 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AU705484B2 (en) * 1994-01-07 1999-05-20 Mochida Pharmaceutical Co., Ltd. Ligand that binds fas antigen
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
EP1294904A1 (en) * 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CN101517075A (zh) * 2006-07-13 2009-08-26 中外制药株式会社 细胞死亡诱导剂
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
PT2925782T (pt) * 2012-12-03 2020-04-22 Novimmune Sa Anticorpos anti-cd47 e métodos de utilização destes
JP2016510319A (ja) 2012-12-28 2016-04-07 アッヴィ・インコーポレイテッド 多価結合タンパク質組成物
WO2014201378A1 (en) * 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
JP6839101B2 (ja) * 2015-06-15 2021-03-03 ヌマブ セラピューティクス アクチェンゲゼルシャフト ヘテロ二量体多重特異性抗体フォーマット

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135345A1 (en) * 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLAUDIA C. ROSKOPF ET AL,, T CELL-RECRUITING TRIPLEBODY 19-3-19 MEDIATES SERIAL LYSIS OF MALIGNANT B-LYMPHOID CELLS BY A SINGLE T CELL, 23 July 2014 (2014-07-23) *
KIPRIYANOV S M ET AL,, BISPECIFIC TANDEM DIABODY FOR TUMOR THERAPY WITH IMPROVED ANTIGEN BINDING AND PHARMACOKINETICS, 15 August 1999 (1999-08-15) *
SCHUBERT INGO ET AL,, A DUAL-TARGETING TRIPLEBODY MEDIATES PREFERENTIAL REDIRECTED LYSIS OF ANTIGEN DOUBLE-POSITIVE OVER SINGLE-POSITIVE LEUKEMIC CELLS., 31 January 2014 (2014-01-31) *
SCHUBERT INGO ET AL,, A SINGLE-CHAIN TRIPLEBODY WITH SPECIFICITY FOR CD19 AND CD33 MEDIATES EFFECTIVE LYSIS OF MIXED LINEAGE LEUKEMIA CELLS BY DUAL TARGETING., 31 December 2011 (2011-12-31) *
UWE REUSCH ET AL,, A NOVEL TETRAVALENT BISPECIFIC TANDAB (CD30/CD16A) EFFICIENTLY RECRUITS NK CELLS FOR THE LYSIS OF CD30 + TUMOR CELLS, 26 March 2014 (2014-03-26) *

Also Published As

Publication number Publication date
CA3001765A1 (en) 2017-04-20
US11572415B2 (en) 2023-02-07
RU2018126966A (ru) 2020-02-10
JP2018537415A (ja) 2018-12-20
AU2016336866B2 (en) 2023-05-25
IL258638B (en) 2022-12-01
US20190040155A1 (en) 2019-02-07
EP3362478A1 (en) 2018-08-22
JP6936497B2 (ja) 2021-09-15
RU2018126966A3 (cg-RX-API-DMAC7.html) 2020-04-20
SG11201803083XA (en) 2018-05-30
IL258638A (en) 2018-06-28
AU2016336866A1 (en) 2018-05-10
EP3156417A1 (en) 2017-04-19
MX2018004547A (es) 2018-11-09
ZA201802543B (en) 2020-01-29
KR20180057720A (ko) 2018-05-30
BR112018007445A2 (pt) 2019-12-10
SG10202004094VA (en) 2020-05-28
WO2017064221A1 (en) 2017-04-20
CN108473577A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
US11572415B2 (en) Multivalent FV antibodies
US20220048994A1 (en) Trifunctional antigen-binding molecule
US20240294647A1 (en) Uses of nk cell engaging antibody fusion constructs for treatments
US20240425616A1 (en) Bispecific t cell activating antigen binding molecules
CN110382539B (zh) 用于cd16a定向的nk细胞结合的串联双抗体
EP3600407A1 (en) Improved antigen binding receptors
KR20200026995A (ko) 향상된 이중 특이성 폴리펩티드 분자
RU2785766C9 (ru) Мультивалентные fv-антитела
RU2785766C2 (ru) Мультивалентные fv-антитела
US20250312452A1 (en) Antibody targeting claudin18.2 and its applications
HK1260025A1 (en) Multivalent fv antibodies
CA3210650A1 (en) Bispecific antibodies enhancing cell mediated immune responses
NZ721138B2 (en) Bispecific t cell activating antigen binding molecules
NZ721138A (en) Bispecific t cell activating antigen binding molecules